Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-01Clinical Trial Update: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma [Phase 2]
This Phase 2 trial evaluating NIR178 in combination with PDR001 across multiple solid tumors and non-Hodgkin lymphoma was terminated, with r…
-
FDA approval · 2024-03-01FDA Approved: RYBREVANT — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for Rybrevant (amivantamab-vmjw) from Janssen Biotech, Inc.; the snippet does not specify the ne…
-
CLINICAL_TRIALS trial_result · 2024-03-01Clinical Trial Update: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) [Phase 2]
Phase 2 trial update investigating atezolizumab in advanced non-small cell lung cancer with rare histologies (CHANCE trial) has completed.
-
FDA approval · 2024-02-29FDA Approved: PEMETREXED — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for a generic pemetrexed disodium product from BluePoint Laboratories.
-
FDA approval · 2024-02-29FDA Approved: PEMETREXED — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for pemetrexed disodium (Pemetrexed) submitted by BluePoint Laboratories.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-02-29Clinical Trial Update: Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study [Phase 2]
Phase 2 translational and biomarker study evaluating durvalumab after chemoradiotherapy for non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial assessing BMS-986207 with nivolumab and ipilimumab as first-line treatment for stage IV non-small cell lung cancer has complet…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
A Phase 1/2 study evaluating lazertinib in EGFR mutation–positive advanced non-small cell lung cancer has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Pembrolizumab + Idelalisib for Lung Cancer Study [Phase 1, Phase 2]
A phase 1/2 study evaluating pembrolizumab with idelalisib in non-small cell lung cancer (including metastatic disease) was terminated with …
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib [Phase 2]
A Phase 2 clinical trial investigating mechanisms of resistance to osimertib in EGFR-mutated, non-pretreated advanced non-small cell lung ca…
-
CLINICAL_TRIALS research · 2024-02-28Clinical Trial Update: Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC [Phase 2]
A Phase 2 clinical trial investigating whether combining SBRT and immunotherapy can induce abscopal effects in advanced non-small cell lung …
-
CLINICAL_TRIALS withdrawal · 2024-02-28Clinical Trial Update: Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen [Phase 4]
Phase 4 trial of pemetrexed plus apatinib maintenance in advanced non-squamous non-small cell lung cancer was withdrawn.
-
FDA approval · 2024-02-27FDA Approved: MEKINIST — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MEKINIST (trametinib) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2024-02-26Clinical Trial Update: A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 4]
A Phase 4 trial evaluating camrelizumab in combination with chemotherapy with or without thalidomide as first-line treatment for advanced no…
-
CLINICAL_TRIALS trial_result · 2024-02-15Clinical Trial Update: Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) [Phase 3]
This update reports the completion and posted results from the Phase 3 MK-3475-091/KEYNOTE-091 trial comparing pembrolizumab to placebo as a…
-
FDA approval · 2024-02-15FDA Approved: TEPMETKO — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for Tepmetko (tepotinib hydrochloride) from EMD Serono, Inc., expanding its approved indications…
-
CLINICAL_TRIALS trial_result · 2024-02-15Clinical Trial Update: Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC [Phase 2]
Phase 2 clinical trial evaluating metronomic oral vinorelbine in combination with tislelizumab for EGFR/ALK-negative advanced non-small cell…
-
CLINICAL_TRIALS trial_result · 2024-02-12Clinical Trial Update: A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC [Phase 3]
Phase 3 trial comparing SY-3505 to crizotinib in first-line ALK-positive non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-02-09Clinical Trial Update: Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC [Phase 2]
Phase 2 trial updating osimertinib with or without savolitinib as first-line in de novo MET-positive, EGFR-mutant non-small cell lung cancer…
-
CLINICAL_TRIALS trial_result · 2024-02-08Clinical Trial Update: Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% [Phase 2]
Phase 2 trial evaluating capmatinib plus pembrolizumab versus pembrolizumab alone in non-small cell lung cancer with PD-L1 expression ≥50%; …
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: Accelerated Radio-Immunotherapy for Lung Cancer [Phase 2]
Phase 2 clinical trial on accelerated radio-immunotherapy for stage III non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers [Phase 2]
Phase 2 trial update assessing safety of pentoxifylline and vitamin E with SABR in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations [Phase 2]
Phase 2 study evaluating Capmatinib with Spartalizumab or placebo in advanced MET exon 14 skipping NSCLC was terminated; results have been p…
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial update for BIBW 2992 (neratinib), an irreversible EGFR and HER-2 inhibitor, in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-02-05Clinical Trial Update: A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer [Phase 1]
Phase 1 study evaluating ramucirumab or necitumumab plus osimertinib in non-small cell lung cancer has completed with results posted.